Author:
Seo Boogyung,Rider Nathan,Rioux William,Teare Adrian,Jones Stephanie,Taplay Pamela,Monty Ghosh S.
Abstract
Abstract
Introduction
Unregulated supply of fentanyl and adulterants continues to drive the overdose crisis. Mobile Overdose Response Services (MORS) are novel technologies that offer virtual supervised consumption to minimize the risk of fatal overdose for those who are unable to access other forms of harm reduction. However, as newly implemented services, they are also faced with numerous limitations. The aim of this study was to examine the facilitators and barriers to the adoption of MORS in Canada.
Methods
A total of 64 semi-structured interviews were conducted between November 2021 and April 2022. Participants consisted of people who use substances (PWUS), family members of PWUS, health care professionals, harm reduction workers, MORS operators, and members of the general public. Inductive thematic analysis was used to identify the major themes and subthemes.
Results
Respondents revealed that MORS facilitated a safe, anonymous, and nonjudgmental environment for PWUS to seek harm reduction and other necessary support. It also created a new sense of purpose for operators to positively contribute to the community. Further advertising and promotional efforts were deemed important to increase its awareness. However, barriers to MORS implementation included concerns regarding privacy/confidentiality, uncertainty of funding, and compassion fatigue among the operators.
Conclusion
Although MORS were generally viewed as a useful addition to the currently existing harm reduction services, it’s important to monitor and tackle these barriers by engaging the perspectives of key interest groups.
Funder
Health Canada’s Substance Use and Addictions Program (SUAP) Grant
Canadian Institutes of Health Research (CIHR) Grant
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Karamouzian M, Rafat B, Kolla G, Urbanoski K, Atkinson K, Bardwell G, et al. Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: a qualitative analysis. Int J Drug Policy. 2023;120: 104157.
2. Russell C, Law J, Bonn M, Rehm J, Ali F. The increase in benzodiazepine-laced drugs and related risks in Canada: the urgent need for effective and sustainable solutions. Int J Drug Policy. 2023;111: 103933.
3. Boon M, Van Dorp E, Broens S, Overdyk F. Combining opioids and benzodiazepines: effects on mortality and severe adverse respiratory events. Ann Palliat Med. 2020;9(2):542–57.
4. Palis H, Xavier C, Dobrer S, Desai R, Sedgemore K, Scow M, et al. Concurrent use of opioids and stimulants and risk of fatal overdose: a cohort study. BMC Public Health. 2022;22(1):2084.
5. Health Canada. Opioid- and Stimulant-related Harms—Canada.ca [Internet]. 2023 [cited 2023 Jul 19]. https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/